In RCC, particularly, GPR65 inhibition holds promise beyond its potential to bolster ICI activity—particularly given the impact of TME acidosis on PD-L1 expression via STAT pathways [46,47]. This evidence concerns the gene SOAT1 and renal cell carcinoma.